On the positive sideOn the positive side they reinstated guidance and beat the conscensus, the said that they are moving forward with F8 and subcontracting their own bacterial water supply. Target 2024 for Nash and Lypo if they want to continue to have protection. The fact that Nash amendments are not settled yet may mean they might have partner interest in the original P3 agreed trial. The Th1902 may not have yielded 2 positive outcome in one of the basket trial cancer type yet and recruitment could be slower than expected but like Wino said maybe patient dying off because of their advanced status not helping. Anyway Marsolais said he has a Q1 traget for complete recruitment, I don't think he want's to have to explain he mislead us on this one. Trying hard to be positive like Wino since SPCEO seems to be in a bad mood.